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Summary Effects of the novel anti-epileptic drug levetiracetam (50 and 100mg/kg)
on spike and wave discharges (SWDs) of WAG/Rij rats were studied. Levetiracetam
decreased the incidence, average duration, total duration and peak frequency of the
SWDs. There was no difference between the two doses. These results agree with
results obtained in Genetic Absence Epilepsy Rat from Strasbourg (GAERS). Further-
more, the decrease of the SWD peak frequency might support the suggestions that
levetiracetam might have a GABAergic mechanism of action.
© 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Levetiracetam has anti-epileptic properties in a
wide range of animal models.1—4 Gower et al.2
investigated its effects on spike and wave dis-
charges (SWDs) in the electro-encephalogram (EEG)
of the Genetic Absence Epilepsy Rat from Stras-
bourg (GAERS), a model for absence seizures. In
the GAERS, levetiracetam decreased the total du-
ration of the SWDs, during the 2 h after injection,
although in a non-dose-dependent manner (dose
range: 5.4—170mg/kg).2
A similar genetic absence epileptic rat model,
the WAG/Rij strain is studied at our department.5
However, the effects of levetiracetam on SWDs in
the EEG of the WAG/Rij rat have not previously
been investigated. Therefore, the effects of lev-
etiracetam (50 and 100mg/kg) on SWDs in the
EEG of the WAG/Rij rat were investigated in or-
der to replicate and extend the effects found in
GAERS.
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Method
This study was performed in accordance with the
guidelines of the European Community for the use of
experimental animals. Approval of the local ethical
committee for animal studies was obtained.
Eight male WAG/Rij rats, 12 months old, with a
mean body weight of 337 g (S.E.M. = 3 g), housed
on a reversed day—night cycle, were used. A
permanent cortical tripolar electrode (Plastics
One MS-332/2-A) was implanted under isoﬂurane
anaesthesia, coordinates according to Paxinos and
Watson:6 A 2.0, L 3.5 (frontal); A —6.0, L 4.0 (pari-
etal) and the ground electrode over the cerebel-
lum. All rats were used in a previous experiment,
after which the animals were allowed to recover
for at least 2 weeks.
Rats were connected to an EEG cable allowing
free movements and habituated to the experimen-
tal conditions for 30min. Experimental sessions
were performed between 13:30 and 16:00 h in a
room with red lights, on 3 separate days with 7 days
between experimental days. Each rat received all
three treatments. The rats were injected i.p. with
saline (2ml/kg) or 50mg/kg of levetiracetam
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counterbalanced on the ﬁrst 2 days and 100mg/kg
of levetiracetam on the 3rd day. Levetiracetam
(UCB Pharma) was dissolved in saline (2ml/kg).
Directly after the injections the EEG was recorded
during 2 h. The EEG in a bandwidth between 0.1 and
100Hz, was digitalized with a sample frequency of
512Hz, and stored for off-line analysis using the
Windaq system (DATAQ Instruments, Akron, OH,
USA). SWDs were marked after visual inspection
based on the criteria for SWDs as proposed by Van
Luijtelaar and Coenen.5
SWD incidence, average duration and total dura-
tion were determined. The SWD spectral content
was analyzed using a Fast Fourier Transform (FFT)
procedure with a window of 2 s, starting at the be-
ginning of the SWD. The peak frequency was ob-
tained from the results of the FFT.
Statistical analyses on each parameter were per-
formed using a Repeated Measures Procedure in
SPSS 11.5 (SPSS Inc., Chicago, IL, USA) (treatment
as within subject factor, α = 0.05), followed by
post hoc paired t-tests (α = 0.05).
Results
Fig. 1 shows the incidence of SWDs in the upper
panel, the average duration of the SWDs in the ﬁrst
middle panel, the total duration of SWDs in the sec-
ond middle panel and the mean peak frequency in
the lower panel.
Statistical analyses showed:
(1) A decrease in incidence after levetiracetam
(F(2,6) = 8.29; P = 0.019), with a signiﬁ-
cant decrease after 50mg/kg (P < 0.01) and
100mg/kg of levetiracetam (P < 0.01), as com-
pared to saline.
(2) A decrease in average duration after levetirac-
etam (F(2,6) = 25.52; P = 0.001), with a signif-
icant decrease after 50mg/kg (P < 0.001) and
100mg/kg of levetiracetam (P < 0.01), as com-
pared to saline.
(3) A decrease in total duration after levetirac-
etam (F(2,6) = 10.17; P = 0.012), with a sig-
niﬁcant decrease after 50mg/kg (P < 0.01)
and 100mg/kg of levetiracetam (P < 0.01), as
compared to saline.
(4) A decrease in peak frequency after levetirac-
etam (F(2,6) = 7.86; P = 0.021), with a signif-
icant decrease after 50mg/kg (P < 0.01) and
100mg/kg of levetiracetam (P < 0.05), as com-
pared to saline.
There was no signiﬁcant difference between the
two doses of levetiracetam on any of the parame-
ters.
Figure 1 Means (n = 8) and standard errors of the inci-
dence (upper panel), the average duration (ﬁrst middle
panel), the total duration (second middle panel) and the
peak frequency (lower panel) of SWDs per treatment. As-
terisks (∗, ∗∗ or ∗∗∗) indicating that P < 0.05, P < 0.01
or P < 0.001, respectively, in the post hoc paired t-tests.
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Discussion and conclusions
The objective of this study was to investigate ef-
fects of levetiracetam on SWDs in WAG/Rij rats.
The incidence, average duration, total duration and
peak frequency of the SWDs were signiﬁcantly de-
creased after levetiracetam as compared to the
saline condition. However, no dose-dependent ef-
fects were observed.
The non-dose-dependent decrease in total du-
ration of SWDs after levetiracetam agrees with
ﬁndings of Gower et al.2 This decrease in to-
tal duration of SWDs was shown to be the result
of both a decrease in incidence and in average
duration of SWDs. Furthermore, the peak fre-
quency of SWDs was decreased, indicating that
the morphology of the SWDs was affected by lev-
etiracetam. The non-dose dependency of these
effects suggest that the maximal effect of leve-
tiracetam on SWDs might already be obtained by
the lowest dose tested (50mg/kg), suggesting that
levetiracetam is not likely to completely abolish
the SWDs. Indeed, a dose-dependent decrease in
SWD activity after lower doses of levetiracetam
(5.4 and 17.0mg/kg) was observed on low dose
pentylenetetrazol-induced SWDs in rats.7
Previously, we found that the gamma-aminobut-
yric acid (GABA) transaminase inhibitor vigabatrin
decreased the peak frequency of SWDs, suggesting
that a GABAergic component might be responsi-
ble for frequency modulation of SWDs.8 Accord-
ingly, Destexhe9 suggests that the peak frequency
of the SWDs can be determined by the balance
between GABAA and GABAB conductances. Inter-
estingly, levetiracetam decreases the peak fre-
quency of SWDs as well. Indeed, Löscher et al.10
reported some subtle signiﬁcant effects on GABA
turnover differing over time and brain region, and
Rigo et al.11 reported that levetiracetam reverses
the negative allosteric modulation of GABAA re-
ceptors by Zn2+ and -carbolines, both of these
effects might affect the balance between GABAA
and GABAB neurotransmission. However, despite
suggestions that levetiracetam might have some
GABAergic properties,2,3,10—14 no clear effects of
levetiracetam on other GABA-related parameters
have been found so far: no direct effects at the
GABAA or GABAB receptor,15,16 no effects on brain
GABA concentrations or release of GABA,17,18 no
effects on the activities of both GABA-synthesizing
and GABA-degrading enzymes,10,17 nor on neuronal
voltage14 and current responses to GABA,11 have
been found.
In conclusion, levetiracetam has some anti-
epileptic properties in both the GAERS and the
WAG/Rij rat models of absence epilepsy: levetirac-
etam, in contrast to the GABAergic drug vigaba-
trin, decreases the duration and the incidence of
SWDs. Furthermore, levetiracetam decreased the
peak frequency of the SWDs, similar to vigabatrin,
suggesting some similar mechanism of action.
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